Clinical Study
First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin
Table 2
Safety of VCM versus that of PCM by questionnaire.
| | Any (AEQ 2 or 3) | AEQ 3 | | VCM | PCM | | VCM | PCM | |
| | Diarrhea | 5.0% | 6.7% | 1 | 0% | 0% | 1 | | Dysgeusia | 0% | 6.7% | 0.38 | 0% | 6.7% | 0.51 | | Nausea | 15.0% | 0% | 0.06 | 10.0% | 0% | 0.16 | | Anorexia | 10.0% | 3.3% | 0.56 | 5.0% | 3.3% | 1 | | Abdominal pain | 15.0% | 3.3% | 0.29 | 5.0 | 0% | 0.40 | | Heart burn | 10.0% | 6.7% | 1 | 0% | 3.3% | 1 | | Hives | 0% | 3.3% | 1 | 0% | 3.3% | 1 | | Headache | 10.0% | 0% | 0.16 | 5.0% | 0% | 0.40 | | Abdominal fullness | 30.0% | 3.3% | 0.012 | 15.0% | 0% | 0.06 | | Belch | 5.0% | 0% | 0.40 | 0% | 0% | 1 | | Vomiting | 0% | 0% | 1 | 0% | 0% | 1 | | General malaise | 15.0% | 3.3% | 0.29 | 0% | 3.3% | 1 | | Others | 5.0% | 3.3% | 1 | 0% | 0% | 1 |
|
|
AEQ: adverse effects questionnaire; AEQ 2: moderate; AEQ 3: strong, VCM: vonoprazan/CAM/MNZ 1-week eradication therapy; PCM: PPI (LPZ or ESO)/CAM/MNZ 1-week eradication therapy.
|
